The pharmacological effect of inhibition of NTSR1 signaling using siRNAs or SR48692 has been already estimated in a wide variety of cancers, such as lung cancer, colon cancer, ovarian cancer, melanoma, and glioma [54, 55, 56, 57, 58, 59]. This evidence concerns the gene NTSR1 and ovarian cancer.